
Opinion|Videos|March 10, 2025
Managing Disease Progression After TACE
Author(s)Amit Singal, MD
The panelist discusses how the patient underwent transarterial chemoembolization (TACE) 3 times with an initial partial response. However, at the end of the 6-month treatment period, the patient had disease progression. The panelist advises that the best treatment option for the patient would be systemic therapy.
Advertisement
Video content above is prompted by the following:
- The patient progresses within 1 year of TACE. Please discuss a suitable treatment approach to address disease progression.
- Review case details from the patient’s 6-month follow-up.
- What would your treatment approach look like?
- How would you determine which treatment option would be best for this patient?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
4
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
5


















